San Diego-based CureScience Institute, a non-profit organization dedicated to accelerating novel curative therapies, disclosed on Tuesday that Dr Boris Reznik has been appointed as an Advisory Board member.
Dr Reznik is chairman of Venvalo Group, venture value optimization firm and is a veteran of several startups.
According to CureScience Institute, Dr Reznik has a strong track record of building companies across a diverse set of technologies-based industries, primarily focused on biomedical sciences.
CEO of CureScience Institute, Dr Shashaanka Ashili, commented: "I am delighted to welcome Dr Reznik to our Advisory Board," adding "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr Reznik's counsel as we work towards developing personalized therapeutic approaches."
The National Pharmaceutical Council names new president and chief executive officer
Ascentage Pharma names new independent non-executive director
Applied Pharmaceutical Innovation adds Dr Michael Houghton to Scientific Advisory Board
Russia registers the world's first vaccine against COVID-19 for animals
Exo Therapeutics Names Mahanthappa to Board of Directors, Roberts to Scientific Advisory Board
Astellas Pharma's XOSPATA meets primary overall survival endpoint in phase three confirmatory trial
Vitelliform Maculopathy Patient Treated in Israel with OpRegen Under Named Patient Compassionate Use
Johnson and Johnson Executive Wengel Named to Labcorp Board of Directors
Brazil's Butantan Institute to seek regulatory approval for trials of new COVID-19 vaccine